Discovery of a selective irreversible BMX inhibitor for prostate cancer

ACS Chemical Biology

Volumn 8, Issue 7, 2013, Pages 1423-1428

  Liu, Feiyang ^a,b   Zhang, Xin ^a,b   Weisberg, Ellen ^c   Chen, Sen ^b   Hur, Wooyoung ^b   Wu, Hong ^a,b   Zhao, Zheng ^a   Wang, Wenchao ^a,b   Mao, Mao ^a   Cai, Changmeng ^b   Simon, Nicholas I ^b   Sanda, Takaomi ^c   Wang, Jinhua ^b   Look, A Thomas ^c   Griffin, James D ^c   Balk, Steven P ^b   Liu, Qingsong ^a,b   Gray, Nathanael S ^b  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BMXIN 1; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; IC 50; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DISCOVERY; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDONES; SULFONAMIDES;

EID: 84880532700     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4000629     Document Type: Article

References (16)

1. Qiu, Y. and Kung, H. J. (2000) Signaling network of the Btk family kinases Oncogene 19, 5651-5661
2. Jiang, X., Borgesi, R. A., McKnight, N. C., Kaur, R., Carpenter, C. L., and Balk, S. P. (2007) Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells J. Biol. Chem. 282, 32689-32698
3. Citri, A., Alroy, I., Lavi, S., Rubin, C., Xu, W., Grammatikakis, N., Patterson, C., Neckers, L., Fry, D. W., and Yarden, Y. (2002) Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy EMBO J. 21, 2407-2417
4. Dai, B., Kim, O., Xie, Y., Guo, Z., Xu, K., Wang, B., Kong, X., Melamed, J., Chen, H., Bieberich, C. J., Borowsky, A. D., Kung, H. J., Wei, G., Ostrowski, M. C., Brodie, A., and Qiu, Y. (2006) Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse Cancer Res. 66, 8058-8064
5. Dai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., Kong, X., Melamed, J., Qiu, S., Chen, H., and Qiu, Y. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells Cancer Res. 70, 5587-5596
6. Wissner, A. and Mansour, T. S. (2008) The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 341, 465-477
7. Hur, W., Velentza, A., Kim, S., Flatauer, L., Jiang, X., Valente, D., Mason, D. E., Suzuki, M., Larson, B., Zhang, J., Zagorska, A., Didonato, M., Nagle, A., Warmuth, M., Balk, S. P., Peters, E. C., and Gray, N. S. (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase Bioorg. Med.Chem. Lett. 18, 5916-5919
8. Fabian, M. A., Biggs, W. H., III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23, 329-336
9. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26, 127-132
10. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
11. Liu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., and Gray, N. S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9- (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer J. Med. Chem. 53, 7146-7155
12. Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K. K., Eck, M. J., Gray, N. S., and Janne, P. A. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462, 1070-1074
13. Melnick, J. S., Janes, J., Kim, S., Chang, J. Y., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J. T., Garcia, M. E., Hood, T. L., Beigi, R., Xia, G., Harig, R. A., Asatryan, H., Yan, S. F., Zhou, Y., Gu, X. J., Saadat, A., Zhou, V., King, F. J., Shaw, C. M., Su, A. I., Downs, R., Gray, N. S., Schultz, P. G., Warmuth, M., and Caldwell, J. S. (2006) An efficient rapid system for profiling the cellular activities of molecular libraries Proc. Natl. Acad. Sci. U.S.A. 103, 3153-3158
14. Warmuth, M., Kim, S., Gu, X. J., Xia, G., and Adrian, F. (2007) Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 19, 55-60
15. Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., and Buggy, J. J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 107, 13075-13080
16. Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E., and Fowler, N. H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J. Clin. Oncol. 31, 88-94